Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT1190B in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
NCT07470073Phase 1Recruiting
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT-1190B in B-cell acute lymphoblastic leukemia (B-ALL). Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events at 12 months. Started Apr 2026; status: recruiting.
02
Drugs
CT-1190B
03
Conditions
B-cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07470073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07470073.